Press release
Pulmonary Arterial Hypertension Market Growth Projections 2024-2034: DelveInsight Analysis | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros Therapeutics
DelveInsight's "Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Pulmonary Arterial Hypertension, historical and forecasted epidemiology as well as the Pulmonary Arterial Hypertension market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The Pulmonary Arterial Hypertension market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pulmonary Arterial Hypertension pipeline products will significantly revolutionize the Pulmonary Arterial Hypertension market dynamics.
To Know in detail about the Pulmonary Arterial Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pulmonary Arterial Hypertension Market Forecast [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Pulmonary Arterial Hypertension Market Report:
*
The Pulmonary Arterial Hypertension (PAH) market size across the seven major markets (7MM) was estimated at around USD 6,971 million in 2025 and is expected to expand at a CAGR of 6.3% between 2024 and 2034.
*
In November 2025, Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage biopharmaceutical company focused on developing treatments for cardiopulmonary diseases such as pulmonary arterial hypertension (PAH), announced that it plans to advance IKT-001 into a global pivotal Phase 3 clinical trial for PAH. The Phase 3 study, titled IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is expected to begin in the first quarter of 2026.
*
In September 2025, AllRock Bio Inc., a clinical-stage biotech company developing therapies for cardiopulmonary and fibrotic diseases, announced a $50 million Series A financing round co-led by Versant Ventures and Westlake BioPartners. The funding will support the advancement of its lead candidate, ROC-101-an oral, first-in-class pan-rho-associated protein kinase (ROCK) inhibitor exclusively licensed from Sanofi-into Phase 2 clinical trials. ROC-101 is being developed to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (ILD-PH), both life-threatening conditions with poor five-year survival rates of 57% and 38%. By targeting inflammatory, proliferative, and fibrotic remodeling driven by both ROCK1 and ROCK2, ROC-101 holds promise to meet a major unmet need in these patient populations.
*
In August 2025, Cereno Scientific's lead candidate, CS1, has been granted FDA Fast Track designation for pulmonary arterial hypertension, acknowledging its promise as a novel and potentially disease-modifying therapy for this rare and severe condition.
*
In August 2025, VASTHERA Co., Ltd. announced FDA clearance of its Investigational New Drug (IND) application to begin a Phase 1 trial for VTB-10, a novel candidate for pulmonary arterial hypertension (PAH). Developed via the company's proprietary Redoxizyme Trademark platform, VTB-10 is a first-in-class small molecule enzyme (Chemzyme) designed to mimic the function of peroxiredoxin (PRX), which is deficient in PAH lesions. Preclinical data showed that VTB-10 not only reversed abnormal vascular remodeling but also restored healthy endothelial function, offering a dual mechanism of action that sets it apart from current treatment options.
*
In March 2025, Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, has shared initial results from its Phase 3 ZENITH trial evaluating WINREVAIR Trademark (sotatercept-csrk) versus placebo in adults with pulmonary arterial hypertension (PAH, Group 1 PH), classified as WHO functional class III or IV and at high risk of mortality, despite receiving the maximum tolerated background PAH therapy. With a median follow-up of 10.6 months (range: 0.3-26.1), WINREVAIR significantly reduced the relative risk of major morbidity and mortality events-including all-cause death, lung transplantation, or PAH-related hospitalization ( greater than or equal to 24 hours)-by 76% (HR=0.24 [95% CI, 0.13-0.43]; p
*
In January 2025, Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced preliminary findings from its Phase 3 ZENITH trial assessing WINREVAIR Trademark (sotatercept-csrk) against placebo in adults with pulmonary arterial hypertension (PAH, Group 1 PH), specifically those categorized as WHO functional class III or IV and considered at high risk of mortality despite being on optimized background PAH treatment. Over a median follow-up period of 10.6 months (range: 0.3-26.1), WINREVAIR demonstrated a 76% reduction in the relative risk of major morbidity and mortality events-defined as all-cause death, lung transplant, or PAH-related hospitalization lasting 24 hours or more-compared to placebo (HR=0.24 [95% CI, 0.13-0.43]; p
*
According to DelveInsight's estimates, Germany held the largest Pulmonary Arterial Hypertension (PAH) market in EU4 and the UK, valued at approximately USD 80 million in 2024, followed by France at USD 70 million, while Spain recorded the smallest PAH treatment market size at USD 45 million in the same year.
*
Several therapies are anticipated to be launched during the forecast period (2025-2034) for Pulmonary Arterial Hypertension treatment, including ralinepag (United Therapeutics), RT234 (vardenafil inhalation powder) (Respira Therapeutics), Seralutinib (GB002) (Gossamer Bio), YUTREPIA (treprostinil) (Liquidia Technologies), and L606 (liposomal treprostinil) (Pharmosa Biopharm/Liquidia).
*
According to DelveInsight's estimates, the total prevalence of Pulmonary Arterial Hypertension (PAH) in the 7MM was approximately 112,700 cases in 2024, with numbers projected to rise by 2034.
*
The United States holds the largest proportion of diagnosed prevalent PAH cases among the 7MM, comprising roughly 45% of the total patient population.
*
In 2024, Japan recorded the second-highest number of diagnosed PAH cases among the 7MM, with approximately 23,000 cases reported.
*
In 2024, EU4 and the UK reported around 26,000 treated PAH cases, with figures expected to rise by 2034.
*
Key Pulmonary Arterial Hypertension Companies: Aerovate Therapeutics, Novartis, Keros Therapeutics, Vigonvita Life Sciences, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, Lung Biotechnology PBC, United Therapeutics, Gilead Science, Acceleron Pharma, Eiger BioPharmaceuticals, AstraZeneca, and others
*
Key Pulmonary Arterial Hypertension Therapies: AV-101, LTP001, KER-012, TPN171H, Treprostinil Palmitil, Satralizumab (Genetical Recombination), Sotatercept, Macitentan, ACT-293987, GB002 (seralutinib), Parenteral Treprostinil, Ralinepag, Selonsertib, Sotatercept, ubenimex, Olaparib, and others
*
The Pulmonary Arterial Hypertension epidemiology based on gender analyzed that females are more affected with Pulmonary Arterial Hypertension than males
*
The Pulmonary Arterial Hypertension market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pulmonary Arterial Hypertension pipeline products will significantly revolutionize the Pulmonary Arterial Hypertension market dynamics.
Pulmonary Arterial Hypertension Overview
When measured by right heart catheterization, pulmonary hypertension (PH) is defined as mean pulmonary artery pressure greater than 25 mm Hg at rest or greater than 30 mm Hg during activity. PH has been classified into five groups by the World Health Organization (WHO) on the basis of shared pathophysiology, clinical presentation, and available treatments.
Get a Free sample for the Pulmonary Arterial Hypertension Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market [https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Pulmonary Arterial Hypertension Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Pulmonary Arterial Hypertension Epidemiology Segmentation:
The Pulmonary Arterial Hypertension market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Pulmonary Arterial Hypertension
*
Prevalent Cases of Pulmonary Arterial Hypertension by severity
*
Gender-specific Prevalence of Pulmonary Arterial Hypertension
*
Diagnosed Cases of Episodic and Chronic Pulmonary Arterial Hypertension
Download the report to understand which factors are driving Pulmonary Arterial Hypertension epidemiology trends @ Pulmonary Arterial Hypertension Epidemiology Forecast [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Pulmonary Arterial Hypertension Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Arterial Hypertension market or expected to get launched during the study period. The analysis covers Pulmonary Arterial Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Pulmonary Arterial Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Pulmonary Arterial Hypertension Therapies and Key Companies
*
AV-101: Aerovate Therapeutics
*
LTP001: Novartis
*
KER-012: Keros Therapeutics
*
TPN171H: Vigonvita Life Sciences
*
Treprostinil Palmitil: Insmed Incorporated
*
Satralizumab (Genetical Recombination): Chugai Pharmaceutical
*
Sotatercept: Merck Sharp & Dohme
*
Macitentan: Janssen Pharmaceutical
*
ACT-293987: Actelion
*
GB002 (seralutinib): Gossamer Bio
*
Parenteral Treprostinil: Lung Biotechnology PBC
*
Ralinepag: United Therapeutics
*
Selonsertib: Gilead Sciences
*
Sotatercept: Acceleron Pharma
*
ubenimex: Eiger BioPharmaceuticals
*
Olaparib: AstraZeneca
Discover more about therapies set to grab major Pulmonary Arterial Hypertension market share @ Pulmonary Arterial Hypertension Treatment Landscape [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Pulmonary Arterial Hypertension Market Strengths
*
Better understanding of disease pathophysiology and genetics has improved diagnosis and treatment, reducing mortality
*
There have been significant developments in the treatment regime leading to the approval of novel therapies and more defined treatment guidelines
Pulmonary Arterial Hypertension Market Opportunities
*
Further research on diagnostic and prognostic blood biomarkers in asymptomatic or specific at-risk populations to improve diagnosis and develop novel treatment options
*
The increasing prevalence of PAH, along with government support for the development of orphan drugs, provide companies with an excellent opportunity to invest in the PAH market
Scope of the Pulmonary Arterial Hypertension Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Pulmonary Arterial Hypertension Companies: Aerovate Therapeutics, Novartis, Keros Therapeutics, Vigonvita Life Sciences, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, Lung Biotechnology PBC, United Therapeutics, Gilead Science, Acceleron Pharma, Eiger BioPharmaceuticals, AstraZeneca, and others
*
Key Pulmonary Arterial Hypertension Therapies: AV-101, LTP001, KER-012, TPN171H, Treprostinil Palmitil, Satralizumab (Genetical Recombination), Sotatercept, Macitentan, ACT-293987, GB002 (seralutinib), Parenteral Treprostinil, Ralinepag, Selonsertib, Sotatercept, ubenimex, Olaparib, and others
*
Pulmonary Arterial Hypertension Therapeutic Assessment: Pulmonary Arterial Hypertension current marketed and Pulmonary Arterial Hypertension emerging therapies
*
Pulmonary Arterial Hypertension Market Dynamics: Pulmonary Arterial Hypertension market drivers and Pulmonary Arterial Hypertension market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Pulmonary Arterial Hypertension Unmet Needs, KOL's views, Analyst's views, Pulmonary Arterial Hypertension Market Access and Reimbursement
To know more about Pulmonary Arterial Hypertension companies working in the treatment market, visit @ Pulmonary Arterial Hypertension Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Pulmonary Arterial Hypertension Market Report Introduction
2. Executive Summary for Pulmonary Arterial Hypertension
3. SWOT analysis of Pulmonary Arterial Hypertension
4. Pulmonary Arterial Hypertension Patient Share (%) Overview at a Glance
5. Pulmonary Arterial Hypertension Market Overview at a Glance
6. Pulmonary Arterial Hypertension Disease Background and Overview
7. Pulmonary Arterial Hypertension Epidemiology and Patient Population
8. Country-Specific Patient Population of Pulmonary Arterial Hypertension
9. Pulmonary Arterial Hypertension Current Treatment and Medical Practices
10. Pulmonary Arterial Hypertension Unmet Needs
11. Pulmonary Arterial Hypertension Emerging Therapies
12. Pulmonary Arterial Hypertension Market Outlook
13. Country-Wise Pulmonary Arterial Hypertension Market Analysis (2020-2034)
14. Pulmonary Arterial Hypertension Market Access and Reimbursement of Therapies
15. Pulmonary Arterial Hypertension Market Drivers
16. Pulmonary Arterial Hypertension Market Barriers
17. Pulmonary Arterial Hypertension Appendix
18. Pulmonary Arterial Hypertension Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
*
The Pulmonary Arterial Hypertension (PAH) market size across the seven major markets (7MM) was estimated at around USD 6,971 million in 2025 and is expected to expand at a CAGR of 6.3% between 2024 and 2034.
*
In November 2025, Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage biopharmaceutical company focused on developing treatments for cardiopulmonary diseases such as pulmonary arterial hypertension (PAH), announced that it plans to advance IKT-001 into a global pivotal Phase 3 clinical trial for PAH. The Phase 3 study, titled IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is expected to begin in the first quarter of 2026.
*
In September 2025, AllRock Bio Inc., a clinical-stage biotech company developing therapies for cardiopulmonary and fibrotic diseases, announced a $50 million Series A financing round co-led by Versant Ventures and Westlake BioPartners. The funding will support the advancement of its lead candidate, ROC-101-an oral, first-in-class pan-rho-associated protein kinase (ROCK) inhibitor exclusively licensed from Sanofi-into Phase 2 clinical trials. ROC-101 is being developed to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (ILD-PH), both life-threatening conditions with poor five-year survival rates of 57% and 38%. By targeting inflammatory, proliferative, and fibrotic remodeling driven by both ROCK1 and ROCK2, ROC-101 holds promise to meet a major unmet need in these patient populations.
*
In August 2025, Cereno Scientific's lead candidate, CS1, has been granted FDA Fast Track designation for pulmonary arterial hypertension, acknowledging its promise as a novel and potentially disease-modifying therapy for this rare and severe condition.
*
In August 2025, VASTHERA Co., Ltd. announced FDA clearance of its Investigational New Drug (IND) application to begin a Phase 1 trial for VTB-10, a novel candidate for pulmonary arterial hypertension (PAH). Developed via the company's proprietary Redoxizyme Trademark platform, VTB-10 is a first-in-class small molecule enzyme (Chemzyme) designed to mimic the function of peroxiredoxin (PRX), which is deficient in PAH lesions. Preclinical data showed that VTB-10 not only reversed abnormal vascular remodeling but also restored healthy endothelial function, offering a dual mechanism of action that sets it apart from current treatment options.
*
In March 2025, Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, has shared initial results from its Phase 3 ZENITH trial evaluating WINREVAIR Trademark (sotatercept-csrk) versus placebo in adults with pulmonary arterial hypertension (PAH, Group 1 PH), classified as WHO functional class III or IV and at high risk of mortality, despite receiving the maximum tolerated background PAH therapy. With a median follow-up of 10.6 months (range: 0.3-26.1), WINREVAIR significantly reduced the relative risk of major morbidity and mortality events-including all-cause death, lung transplantation, or PAH-related hospitalization ( greater than or equal to 24 hours)-by 76% (HR=0.24 [95% CI, 0.13-0.43]; p
*
In January 2025, Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced preliminary findings from its Phase 3 ZENITH trial assessing WINREVAIR Trademark (sotatercept-csrk) against placebo in adults with pulmonary arterial hypertension (PAH, Group 1 PH), specifically those categorized as WHO functional class III or IV and considered at high risk of mortality despite being on optimized background PAH treatment. Over a median follow-up period of 10.6 months (range: 0.3-26.1), WINREVAIR demonstrated a 76% reduction in the relative risk of major morbidity and mortality events-defined as all-cause death, lung transplant, or PAH-related hospitalization lasting 24 hours or more-compared to placebo (HR=0.24 [95% CI, 0.13-0.43]; p
*
According to DelveInsight's estimates, Germany held the largest Pulmonary Arterial Hypertension (PAH) market in EU4 and the UK, valued at approximately USD 80 million in 2024, followed by France at USD 70 million, while Spain recorded the smallest PAH treatment market size at USD 45 million in the same year.
*
Several therapies are anticipated to be launched during the forecast period (2025-2034) for Pulmonary Arterial Hypertension treatment, including ralinepag (United Therapeutics), RT234 (vardenafil inhalation powder) (Respira Therapeutics), Seralutinib (GB002) (Gossamer Bio), YUTREPIA (treprostinil) (Liquidia Technologies), and L606 (liposomal treprostinil) (Pharmosa Biopharm/Liquidia).
*
According to DelveInsight's estimates, the total prevalence of Pulmonary Arterial Hypertension (PAH) in the 7MM was approximately 112,700 cases in 2024, with numbers projected to rise by 2034.
*
The United States holds the largest proportion of diagnosed prevalent PAH cases among the 7MM, comprising roughly 45% of the total patient population.
*
In 2024, Japan recorded the second-highest number of diagnosed PAH cases among the 7MM, with approximately 23,000 cases reported.
In 2024, EU4 and the UK reported around 26,000 treated PAH cases, with figures expected to rise by 2034.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pulmonary-arterial-hypertension-market-growth-projections-20242034-delveinsight-analysis-merck-janssen-pharma-aerovate-therapeutics-novartis-insmed-inc-chugai-pharma-keros-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Arterial Hypertension Market Growth Projections 2024-2034: DelveInsight Analysis | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros Therapeutics here
News-ID: 4297467 • Views: …
More Releases from ABNewswire
Genloop Meets Prime Minister Narendra Modi to Advance Vision for Ethical, Scalab …
Genloop leaders met with India's Prime Minister to discuss advancing ethical, scalable AI from innovation to real-world deployment.
Santa Monica, CA - January 14, 2026 - Genloop [https://genloop.ai/?utm_source=ABNews&utm_medium=email&utm_campaign=1752vc], a portfolio company of 1752vc [http://1752.vc/?utm_source=abnews] (formerly Pegasus Angel Accelerator), announced that its leadership met with the Prime Minister of India, Narendra Modi, at his official residence, 7 Lok Kalyan Marg, for a high-level strategic discussion on the future of artificial intelligence in…
Alopecia Areata Market to Witness Promising Upswing by 2034, DelveInsight Foreca …
The Key Alopecia Areata Companies in the market include - Eli Lilly and Company/Incyte Corporation, Pfizer, Legacy Healthcare, Pfizer, Q32 Bio Inc., AbbVie, Amgen, Concert Pharmaceuticals, Bristol-Myers Squibb, Reistone Biopharma, Inmagene LLC, Suzhou Zelgen Biopharma, Nektar Therapeutics, AnaptysBio, Inc., LEO Pharma, Eli Lilly and Company, and others.
The Alopecia Areata market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage…
Neko Case Neon Grey Midnight Green 2026: Affordable Tickets + CITY10 Code for In …
Neko Case's Neon Grey Midnight Green Tour rocks North America in 2026, celebrating her acclaimed Sept 2025 album-first new solo work since 2018-with raw, live-recorded tracks, powerful vocals, and hits like "Hold On, Hold On." Catch her with Des Demonas (East/Midwest) or Destroyer (West) from Jan 8 Montreal to March dates in CO, CA & more!
Neko Case [https://www.capitalcitytickets.com/Neko-Case-Tickets] is embarking on her electrifying Neon Grey Midnight Green Tour in 2026,…
Toogood Gold Expands Footprint, Positioned for High-Impact Growth 2026 Alongside …
Toogood Gold Corp. (TSXV: TGC | OTCQB: TGGCF) reported final drilling assays from its 100%-owned Toogood Gold Project in Newfoundland, delivering results that significantly expand the scale, continuity, and upside potential of its gold discovery heading into 2026.
The Company's 2025 drill program confirmed the Quinlan target as a large, coherent gold system, with gold intersected in all 30 drill holes completed to date. High-grade intervals and visible gold were reported…
More Releases for Pulmonary
Innovation In Pulmonary Drug Delivery Devices Industry Trends Gaining Momentum i …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pulmonary Drug Delivery Devices Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for pulmonary drug delivery devices has experienced significant growth in the past few years. The market is projected to increase from $49.52 billion in 2024 to $52.8 billion in 2025,…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
